3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
29
Cetuximab
11
Nivolumab
10
Fluorouracil
8
Cyclophosphamide
8
Cisplatin
8
Carboplatin
8
fludarabine
7
atezolizumab
7
Blood Specimen Collection
7
cemiplimab
6
Radiotherapy
6
Drug Therapy
6
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Paclitaxel
4
Docetaxel
4
Capecitabine
4
Biopsy
4
spartalizumab
3
avelumab
3
Surveys and Questionnaires
3
Pemetrexed
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Ipilimumab
3
Interleukin-2
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
rocakinogene sifuplasmid
×
Gastrointestinal
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled